Immune checkpoint inhibitors and prostate cancer: A new frontier?

Oncology Reviews

Volumn 10, Issue 1, 2016, Pages

  Modena, Alessandra ^a   Ciccarese, Chiara ^a   Iacovelli, Roberto ^a   Brunelli, Matteo ^a   Montironi, Rodolfo ^b   Fiorentino, Michelangelo ^c   Tortora, Giampaolo ^a   Massari, Francesco ^c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

CTLA 4; Immune checkpoint inhibitors; Immunotherapy; PD 1; PD L1; Prostate cancer

Indexed keywords

ADXS 31 142; B7 ANTIGEN; B7 H3 PROTEIN; CANCER VACCINE; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEGARELIX; DNA VACCINE; ENZALUTAMIDE; GOSERELIN; IPILIMUMAB; LEUPRORELIN; MEMBRANE PROTEIN; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; REGULATOR PROTEIN; SIPULEUCEL T; T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN CONTAINING MOLECULE 3; TICILIMUMAB; UNCLASSIFIED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ADAPTIVE IMMUNITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CRYOSURGERY; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84967144662     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.4081/oncol.2016.293     Document Type: Review

References (99)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86.
2. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial. Lancet 2010; 376: 1147-54.
3. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-92.
4. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152-60.
5. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97.
6. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-33.
7. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-23.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next genera tion. Cell 2011; 144: 646-74.
9. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-98.
10. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
11. Massari F, Santoni M, Ciccarese C et al. The immunocheckpoints in modern oncology: the next 15 years. Exp Opin Biol Ther 2015; 15: 917-21.
12. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
13. Cheng ML, Fong L. Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol 2014; 15: 115-26.
14. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353: 1224-35.
15. Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics-Theory. Urology 1981; 17: 40-53.
16. Westdorp H, Sköld AE, Snijer BA, et al. Immunotherapy for prostate cancer: lessons from responses to tumor-Associated antigens. Front Immunol 2014; 5: 191.
17. Ozu C, Nakashima J, Horiguchi Y, et al. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol 2008; 15: 419-22.
18. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000; 19: 1288-96.
19. Ebelt K, Babaryka G, Figel AM, et al. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 2008; 68: 1-10.
20. Gannon PO, Poisson AO, Delvoye N, et al. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348: 9-17.
21. Vesalainen S, Lipponen P, Talja M, et al. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-Term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994; 30A: 1797-803.
22. Hussein MR, Al-Assiri M, Musalam AO. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol 2009; 86: 108-13.
23. Bronte V, Kasic T, Gri G, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005; 20: 1257-68.
24. Ebelt K, Babaryka G, Frankenberger B, et al. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer 2009; 45: 1664-72.
25. Kiniwa Y, Miyahara Y, Wang HY, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007; 13: 6947-58.
26. Kärjä V, Aaltomaa S, Lipponen P, et al. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 2005; 25: 4435-38.
27. Davidsson S, Ohlson AL, Andersson SO, et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Mod Pathol 2013; 26: 448-55.
28. Tang S, Moore ML, Grayson JM, et al. Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res 2012; 72: 1975-85.
29. Flammiger A, Weisbach L, Huland H, et al. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer 2013; 49: 1273-79.
30. Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005; 175: 2741-53.
31. Wilson CA, Mrose SA, Thomas DW. Enhanced production of B lymphocytes after castration. Blood 1995; 85: 1535-39.
32. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005; 7: 239-49.
33. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001; 98: 14565-70.
34. Antonarakis ES, Kibel A, Tyler RC, et al. Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC). J Clin Oncol 2013; suppl 6: abstr 34.
35. Collins AV, Brodie DW, Gilbert RJ, et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17: 201-10.
36. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229: 12-26.
37. Wing K, Yamaguchi T, Sakaguchi S. Cell-Autonomous and -nonautonomous roles of CTLA-4 in immune regulation. Trends Immunol 2011; 32: 428-33.
38. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol 2004; 58: 862-70.
39. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11: 728-34.
40. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15: 5379-88.
41. Finkelstein SE, Salenius S, Mantz CA, et al. Combining immunotherapy and radiation for prostate cancer. Clin Genitourin Cancer 2015; 13: 1-9.
42. Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 2015; 16: e498-509.
43. Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013; 24: 1813-21.
44. Tollefson MK, Thompson RH, Granberg CF, et al. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patiets with advanced prostate cancer. Genitourinary Cancer Symposium Meeting 2010; abstr 168.
45. Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 501-8.
46. Jochems C, Tucker JA, Tsang KY, et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother 2014; 63: 407-18.
47. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-Transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 509-17.
48. Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 609-15.
49. Small E, Higano C, Tchekmedyian N, et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. ASCO Meeting Abstracts. 2006; 24: 4609.
50. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 700-12.
51. Kittai A, Meshikhes M, Aragon-Ching JB. Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer. Cancer Biol Ther 2014; 15: 1299-300.
52. Parker C. A near miss for prostate cancer immunotherapy. Lancet Oncol 2014; 15: 669-71.
53. McNeel DG, Smith HA, Eickhoff JC, et al. Phase I trial of tremelimumab in combination with short-Term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother 2012; 61: 1137-47.
54. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765-72.
55. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004; 64: 1140-5.
56. Dong H, Strome SE, Salomao DR, et al. Tumor-Associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
57. Zou W, Chen L. Inhibitory B7-family molecules in the tumor microenvironment. Nat Rev Immunol 2008; 8: 467-77.
58. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PDL1) pathway to activate anti-Tumor immunity. Curr Opin Immunol 2012; 24: 207-12.
59. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-30.
60. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32.
61. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced non squamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39.
62. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35.
63. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803-13.
64. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20: 5064-74.
65. Iacovelli R, Nolè F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-Analysis. Target Oncol 2016; 11: 143-8.
66. Grosso J, Horak CE, Inzunza D, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2013; 31 suppl: abstr 3016.
67. Fay AP, Callea M, Gray KP, et al. PD-L1 expression in non-clear cell renal cell carcinoma. J Clin Oncol 2014; 32 suppl 4: abstr 424.
68. Madore J, Vilain R, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015; 28: 245-53.
69. Shim H-J, Hwang J-E, Jung S-I, et al. Clinical impact of programmed cell death ligand 1 (PD-L1), programmed cell death 1 (PD-1), and CD8 expression in pancreatic cancer. J Clin Oncol 2014; 32suppl: abstr e15258.
70. Martin AM, Nirschl TR, Nirschl CJ, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis 2015; 18: 325-32.
71. Massari F, Ciccarese C, Caliò A, et al. Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis. Target Oncol 2015 [Epub ahead of print].
72. Sfanos KS, Bruno TC, Meeker AK, et al. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009; 69: 1694-703.
73. Gevensleben H, Dietrich D, Golletz C, et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res 2015 [Epub ahead of print].
74. Bishop JL, Sio A, Angeles A, et al. PD-L1 is highly expressed in enzalutamide resistant prostate cancer. Oncotarget 2014 [Epub ahead of print].
75. Spary LK, Salimu J, Webber JP, et al. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer. Oncoimmunol 2014; 3: e955331.
76. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
77. Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013; 34: 556-63.
78. Zang X, Thompson RH, Al-Ahmadie HA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 2007; 104: 19458-63.
79. Katayama A, Takahara M, Kishibe K, et al. Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis. Int J Oncol 2011; 38: 1219-26.
80. Tekle C, Nygren MK, Chen YW, et al. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-Associated genes. Int J Cancer 2012; 130: 2282-90.
81. Arigami T, Narita N, Mizuno R, et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 2010; 252: 1044-51.
82. Wu CP, Jiang JT, Tan M, et al. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol 2006; 12: 457-9.
83. Roth TJ, Sheinin Y, Lohse CM, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007; 67: 7893-900.
84. Yuan H, Wei X, Zhang G, et al. B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol 2011; 186: 1093-99.
85. Liu Y, Vlatkovic L, Sæter T, et al. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population Int J Urol 2012; 19: 749-56.
86. Parker AS, Heckman MG, Sheinin Y, et al. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1343-49.
87. Chavin G, Sheinin Y, Crispen PL, et al. Expression of immunosuppresive B7-H3 ligand by hormone-Treated prostate cancer tumors and metastases. Clin Cancer Res 2009; 15: 2174-80.
88. Fan M, Zhuang Q, Chen Y, et al. B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma. Int J Clin Exp Pathol 2014; 7: 6768-75.
89. Krambeck AE, Thompson RH, Dong H, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006; 103: 10391-96.
90. Liu W, Shibata K, Koya Y, et al. B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients. Mol Clin Oncol 2014; 2: 219-25.
91. Chen LJ, Sun J, Wu HY, et al. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother 2011; 60: 1047-55.
92. Arigami T, Uenosono Y, Hirata M, et al. Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J Surg Oncol 2010; 102: 748-52.
93. Qian Y, Yao HP, Shen L, et al. Expression of B7-H4 in prostate cancer and its clinical significance. Zhejiang Da Xue Xue Bao Yi Xue Ban 2010; 39: 345-9.
94. Kreymborg K, Haak S, Murali R, et al. Ablation of B7-H3 but not B7-H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer. Cancer Immunol Res 2015; 3: 849-54.
95. Sakuishi K, Jayaraman P, Behar SM, et al. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 2011; 32: 345-9.
96. Gao X, Zhu Y, Li G, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 2012; 7: e30676.
97. Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-86.
98. Wu J, Liu C, Qian S, et al. The expression of Tim-3 in peripheral blood of ovarian cancer. DNA Cell Biol 2013; 32: 648-53.
99. Piao YR, Jin ZH, Yuan KC, et al. Analysis of Tim-3 as a therapeutic target in prostate cancer. Tumour Biol 2014; 35: 11409-14.